Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Clinical Significance and Treatment

ABSTRACT

This article provides a review of the various types of antiphospholipid (aPL) antibodies and antiphospholipid syndromes, their prevalence, presumed origin, relationship to autoimmunity in general, and their role in the body's defenses and apoptosis. New hypotheses such as the role of antibodies to β2 glycoprotein I (β2GPI) and the signaling of toll-like receptors are also discussed, as is the spectrum of clinical manifestations associated with the demonstration of these antibodies, now assumed to be “pathogenic.” A distinction is made between antibodies present in sera of patients with a variety of microangiopathic syndromes (MAPS; e.g., HELLP syndrome, thrombotic thrombocytopenic purpura, and thrombotic microangiopathic syndromes). In these conditions, the antibodies might not be “pathogenic” but, alternatively, generated by small vessel endothelial damage. These conditions are differentially referred to as microangiopathic antiphospholipid–associated syndromes, and they should be differentiated from the microvascular occlusions that are seen in the antiphospholipid syndrome. Current treatments of the antiphospholipid syndrome are briefly reviewed.

KEYWORDS

Antiphospholipid (aPL) antibodies - antiphospholipid syndromes - APS - treatment

REFERENCES

• 1 Field S L, Brighton T A, McNeil H P, Chesterman C N. Recent insights into antiphospholipid antibody-mediated thrombosis.  Best Pract Res Clin Haematol. 1999;  12 407-422
• 2 Meroni P L, Raschi E, Testoni C, Borghi M O. Endothelial cell activation by antiphospholipid antibodies.  Clin Immunol. 2004;  112 169-174
• 3 Lockshin M D. Update on antiphospholipid syndrome.  Bull NYU Hosp Jt Dis. 2006;  64 57-59
• 4 Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms.  Autoimmun Rev. 2003;  2 86-93
• 5 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update.  Thromb Haemost. 1995;  74 1185-1190
• 6 Fischetti F, Durigutto P, Pellis V et al.. Thrombus formation induced by antibodies to beta-2-glycoprotein I is complement dependent and requires a priming factor.  Blood. 2005;  106 2340-2346
• 7 Czompoly T, Olasz K, Simon D et al.. A possible new bridge between innate and adaptive immunity: are the anti-mitochondrial citrate synthase autoantibodies components of the natural antibody network?.  Mol Immunol. 2006;  43 1761-1768
• 8 Baumgarth N, Tung J W, Herzenberg L A. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion.  Springer Semin Immunopathol. 2005;  26 347-362
• 9 Chang M K, Boullier A, Hartvigsen K et al.. The role of natural antibodies in atherogenesis.  J Lipid Res. 2005;  46 1353-1363
• 10 Binder C J, Silverman G J. Natural antibodies and the autoimmunity of atherosclerosis.  Springer Semin Immunopathol. 2005;  26 385-404
• 11 McIntyre J A, Wagenknecht D R, Faulk W P. Redox-reactive autoantibodies: detection and physiological relevance.  Autoimmun Rev. 2006;  5 76-83
• 12 Blank M, Asherson R A, Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin.  J Clin Immunol. 2004;  24 12-23
• 13 Shovman O, Gilburd B, Barzilai O et al.. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies.  Ann N Y Acad Sci. 2005;  1050 380-388
• 14 Wananukul S, Voramethkul W, Kaewopas Y, Hanvivatvong O. Prevalence of positive antinuclear antibodies in healthy children.  Asian Pac J Allergy Immunol. 2005;  23 153-157
• 15 Shi W, Krilis S A, Chong B H, Gordon S, Chesterman C N. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population.  Aust N Z J Med. 1990;  20 231-236
• 16 McIntyre J A, Wagenknecht D R, Faulk W P. Autoantibodies unmasked by redox reactions.  J Autoimmun. 2005;  24 311-317
• 17 Reipert B M, Tanneberger S, Pannetta A et al.. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?.  Cancer Immunol Immunother. 2005;  54 1038-1042
• 18 Rauch J, Subang R, D'Agnillo P, Koh J S, Levine J S. Apoptosis and the antiphospholipid syndrome.  J Autoimmun. 2000;  15 231-235
• 19 Rauch J, D'Agnillo P, Subang R, Levine J S. Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells.  Thromb Res. 2004;  114 371-382
• 20 Miyakis S, Lockshin M H, Atsumi T et al.. International consensus statement on an update of the international classification for deinite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 21 Asherson R A. The catastrophic antiphospholipid syndrome syndrome.  J Rheumatol. 1992;  19 508-512
• 22 Asherson R A, Pierangeli S S, Cervera R. Is there a microangiopathic antiphospholipid syndrome?.  Ann Rheum Dis. 2007;  66 429-432
• 23 Ter Borg E J, Van Der Meer J, De Wolf J TM et al.. Arterial thrombotic manifestations in young women associated with the lupus antocoagulant.  Clin Rheumatol. 1988;  7 74-79
• 24 Asherson R A, Cervera R. Sneddon's and the “primary” antiphospholipid syndrome: confusion clarified.  J Stroke Cerebrovasc Dis. 1993;  3 121-122
• 25 Gómez-Puerta J A, Cervera R, Calvo L M et al.. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients.  Rheumatology. 2005;  44 95-99
• 26 Asherson R A, Cervera R. Antiphospholipid antibodies and the heart: lessons and pitfalls of the cardiologist.  Circulation. 1991;  84 920-923
• 27 Morton K E, Gavaghan T P, Krilis S A et al.. Coronary artery bypass graft failure: an autoimmune phenomenon?.  Lancet. 1986;  ii 1353-1356
• 28 Sandoval J, Amigo M-C, Barragan R et al.. Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy.  J Rheumatol. 1996;  23 772-775
• 29 Rich S, Kieras K, Hart K, Groves B M, Stobo J D, Brundage B H. Primary pulmonary hypertension.  J Am Coll Cardiol. 1986;  8 1307-1311
• 30 Asherson R A, Cervera R. Pulmonary hypertension, antiphospholipid antibodies and syndromes.  Clin Rev Allergy Immunol. 2007;  32 153-158
• 31 Asherson R A, Cervera R, Pierangeli S S. Microangiopathic antiphospholipid-associated syndromes revisited; new concepts relating to antiphospholipid antibodies and syndromes.  J Rheumatol . 2007;  34 1793-1795
• 32 Hughson M D, Madasdy T, McCarty G A, Stoler C, Min K-W, Silva T. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome.  Am J Kidney Dis. 1992;  20 150-158
• 33 Radhakrishnan J, Williams G S, Appel G B, Cohen D J. Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients.  Am J Kidney Dir. 1994;  23 286-289
• 34 Espinosa G, Santos E, Cervera R et al.. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients.  Medicine (Baltimore). 2003;  82 106-118
• 35 Cervera R, Espinosa G, Cordero A for the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group et al.. Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS.  Semin Arthritis Rheum. 2007;  36 287-296
• 36 Espinosa G, Font J, García-Pagan J C et al.. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients.  Medicine (Baltimore). 2001;  80 345-354
• 37 Triplett D A. Antiphospholipid antibodies and recurrent pregnancy loss.  Am J Reprod Immunol. 1989;  20 52-67
• 38 Cervera R, Piette J C, Font J et al.. on behalf of the “Euro-Phospholipid Project Group.” Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.  Arthritis Rheum. 2002;  46 1019-1027
• 39 Erkan D, Cervera R, Asherson R A. Catastrophic antiphospholipid syndrome: where do we stand?.  Arthritis Rheum. 2003;  48 3320-3327
• 40 Bucciarelli S, Espinoza G, Cervera R et al.. Mortality in the antiphospholipid syndrome; causes of death and prognostic factors in 250 patients.  Arthritis Rheum. 2006;  54 2568-2576
• 41 Erdozain J G, Ruiz-Irastorza G, Egurbide M V et al.. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome [abstract].  Haematologica. 2004;  89 ECR34
• 42 Rubenstein E, Arkfeld D G, Metyas S, Shinada S, Ehresmann S, Liebman H A. Rituximab treatment for resistant antiphospholipid syndrome.  J Rheumatol. 2006;  33 355-357
• 43 Yamazaki M, Kawashima Y, Asakura H, Nakao S. Rituximab decreases antiphospholipid antibody titers and improves hypercoagulable state without recurrent thrombosis: 2-year follow-up [abstract].  Thromb Res. 2004;  114 610
• 44 Crowther M A, Ginsberg J S, Julian J et al.. Comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.  N Engl J Med. 2003;  349 1133-1138
• 45 Finazzi G, Marchioli R, Brancaccio V et al.. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).  J Thromb Haemost. 2005;  3 848-853
• 46 Kearon C. Long-term management of patients after venous thromboembolism.  Circulation. 2004;  110(Suppl 1) 110-118
• 47 Erkan D, Harrison M J, Levy R et al.. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.  Arthritis Rheum. 2007;  56 2382-2391
• 48 Goldstein L B, Adams R, Alberts M J et al.. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council.  Circulation. 2006;  113 e873-e923
• 49 Erkan D, Leibowitz E, Berman J et al.. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations.  J Rheumatol. 2002;  29 843-849
• 50 Erkan D. The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: Review of the literature and management strategies.  Curr Rheumatol Rep. 2002;  4 379-386
• 51 Derksen R H, Khamashta M A, Branch D W. Management of the obstetric antiphospholipid syndrome.  Arthritis Rheum. 2004;  50 1028-1039
• 52 Erkan D, Lockshin M D. New treatments for antiphospholipid syndrome.  Rheum Dis Clin North Am. 2006;  32 129-148

5 deceased